{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:07:59Z","timestamp":1782634079766,"version":"3.54.5"},"reference-count":75,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"abstract":"<jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Abstract:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Since dupilumab approval for moderate-to-severe atopic dermatitis (AD) in 2017, facial rash reports appeared in literature.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    To report facial rash treatment-emergent adverse events (TEAEs) incidence in dupilumab clinical trials for moderate-to-severe AD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Data were pooled from 14 randomized, placebo-controlled dupilumab clinical trials in pediatric (6\u201317 years) and adult (\u226518 years) patients and were searched for facial rash TEAEs occurring during study treatment period, focusing on Medical Dictionary for Regulatory Activities (MedDRA) Lowest Level Terms (LLTs).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Pooled dataset included 1349 placebo-treated and 2615 dupilumab-treated patients. Facial rash incidence was low but slightly higher in dupilumab (dupilumab: 25 [1.0%]; placebo: 9 [0.7%] patients). The following LLT rates were numerically higher in dupilumab than placebo-treated patients: Erythema facial (7 [0.3%, 0.8 number of events (nE)\/100 patient-years (PY)] vs 1 [&lt;0.1%, 0.1 nE\/100PY]); Redness facial (2 [&lt;0.1%, 0.2 nE\/100PY] vs 0); and rash on face (5 [0.2%, 0.4 nE\/100PY] vs 1 [&lt;0.1%, 0.1 nE\/100PY]). Most cases were mild-to-moderate and recovered\/resolved during study period; none led to treatment discontinuation.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:underline>\n                      <jats:bold>\n                        <jats:italic toggle=\"yes\">Conclusions:<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:underline>\n                    Facial rash analysis focused on MedDRA LLTs in dupilumab clinical trials for moderate-to-severe AD showed a small increase in dupilumab-treated patients compared with placebo. Most were mild-to-moderate and not treatment-limiting.\n                  <\/jats:p>","DOI":"10.1177\/17103568251386871","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:37:30Z","timestamp":1761734250000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Facial Rash Events in Dupilumab Phase 3 Atopic Dermatitis Trials: A Pooled Analysis"],"prefix":"10.1177","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[{"name":"From the,  Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Ann &amp; Robert H. Lurie Children\u2019s Hospital, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[{"name":"National Expertise Center of Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health &amp; Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoung","family":"Ahn","sequence":"additional","affiliation":[{"name":"National Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[{"name":"Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA"},{"name":"Center for Medical Dermatology + Immunology Research, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golara","family":"Honari","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Gherardi","sequence":"additional","affiliation":[{"name":"Sanofi, Reading, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Coleman","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lawless","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17703"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092684"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211002979"},{"key":"e_1_3_1_6_2","unstructured":"US Food and Drug Administration. DUPIXENT\u00ae (dupilumab). Highlights of Prescribing Information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761055s054lbl.pdf [Last accessed: February4 2025]."},{"key":"e_1_3_1_7_2","unstructured":"European Medicines Agency. DUPIXENT\u00ae (dupilumab). Summary of Product Characteristics. Available from: https:\/\/www.ema.europa.eu\/documents\/product-information\/dupixent-epar-product-information_en.pdf [Last accessed: February4 2025]."},{"issue":"5","key":"e_1_3_1_8_2","first-page":"1643","article-title":"Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomic regions in pediatric patients 6 years of age and older","volume":"11","author":"Simpson EL","year":"2021","unstructured":"Simpson EL, , Paller AS, , Siegfried EC, et al. Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomic regions in pediatric patients 6 years of age and older. Dermatol Ther (Heidelb). 2021; 11(5):1643\u20131656.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00638-1"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00960-w"},{"key":"e_1_3_1_11_2","unstructured":"Dalia Y Johnson MS. Case report: First reported case of facial rash after dupilumab therapy. In: Practical Dermatology. 2019. Available from: https:\/\/practicaldermatology.com\/youngmd-connect\/resident-resource-center\/case-report-first-reported-case-of-facial-rash-after-dupilumab-therapy-call-for-abstracts\/20499\/#:\u223c:text=Case%20Presentation.%20A%2026-year-old%20white%20woman%20with%20a [Last accessed: February4 2025]."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.08.027"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.020"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2613"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18730"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061982"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00458-6"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1003"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2020.12.6.1063"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.026"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.0316"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0122"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14434"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1624683"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02950-4"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.012"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14799"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14888"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.07.001"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15064"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15140"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18327"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000801"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15471"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2049588"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.070"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18109"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21019"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18450"},{"issue":"4","key":"e_1_3_1_40_2","first-page":"e2022184","article-title":"Dupilumab-associated facial erythema successfully treated with oral ivermectin","volume":"12","author":"Liane JG","year":"2022","unstructured":"Liane JG, , Morgado-Carrasco D. Dupilumab-associated facial erythema successfully treated with oral ivermectin. Dermatol Pract Concept. 2022; 12(4):e2022184.","journal-title":"Dermatol Pract Concept"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17705"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16356"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16322"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14153"},{"issue":"7","key":"e_1_3_1_45_2","first-page":"e27170","article-title":"Dupilumab-associated head and neck dermatitis with ocular involvement in a ten-year-old with atopic dermatitis: A case report and review of the literature","volume":"14","author":"Samia AM","year":"2022","unstructured":"Samia AM, , Cuervo-Pardo L, , Montanez-Wiscovich ME, et al. Dupilumab-associated head and neck dermatitis with ocular involvement in a ten-year-old with atopic dermatitis: A case report and review of the literature. Cureus. 2022; 14(7):e27170.","journal-title":"Cureus"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2035309"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15843"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1027589"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.0023"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2220444"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100096"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.05.021"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18743"},{"key":"e_1_3_1_54_2","unstructured":"European Commission. A guideline on Summary of Product Characteristics (SmPC) September 2009. Available from: https:\/\/health.ec.europa.eu\/document\/download\/6a043dea-7d0f-4252-947b-cef58f53d37e_en [Last accessed: February4 2025]."},{"key":"e_1_3_1_55_2","unstructured":"MedDRA. Introductory guide MedDRA Version 21.0. Available from: https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_21_0_english.pdf [Last accessed: February4 2025]."},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00388-8"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19460"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18476"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16764"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2024.01.002"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.153"},{"issue":"1","key":"e_1_3_1_69_2","first-page":"10","article-title":"Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: Analysis from the Heads Up study","volume":"241","author":"Thyssen JP","year":"2025","unstructured":"Thyssen JP, , Rosmarin D, , Costanzo A, et al. Efficacy and safety of upadacitinib versus dupilumab treatment for moderate-to-severe atopic dermatitis in four body regions: Analysis from the Heads Up study. Dermatology. 2025; 241(1):10\u201318.","journal-title":"Dermatology"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18849"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16383"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2023.132260"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.010"},{"key":"e_1_3_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.12.002"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.11.024"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.017"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17103568251386871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17103568251386871","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17103568251386871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:09:41Z","timestamp":1777399781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/17103568251386871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":75,"alternative-id":["10.1177\/17103568251386871"],"URL":"https:\/\/doi.org\/10.1177\/17103568251386871","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"article-number":"17103568251386871"}}